Hologic, Inc. (NASDAQ:HOLX) Shares Purchased by Principal Financial Group Inc.

Principal Financial Group Inc. boosted its stake in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 3.6% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 269,546 shares of the medical equipment provider's stock after acquiring an additional 9,419 shares during the quarter. Principal Financial Group Inc. owned 0.12% of Hologic worth $21,957,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Andra AP fonden increased its stake in Hologic by 224.5% during the 2nd quarter. Andra AP fonden now owns 95,400 shares of the medical equipment provider's stock worth $7,083,000 after buying an additional 66,000 shares in the last quarter. GAMMA Investing LLC grew its holdings in shares of Hologic by 17.9% during the 3rd quarter. GAMMA Investing LLC now owns 3,832 shares of the medical equipment provider's stock worth $312,000 after purchasing an additional 582 shares during the period. Janus Henderson Group PLC grew its stake in shares of Hologic by 2.9% in the third quarter. Janus Henderson Group PLC now owns 28,776 shares of the medical equipment provider's stock valued at $2,344,000 after buying an additional 800 shares in the last quarter. Quest Partners LLC increased its position in shares of Hologic by 56.1% during the second quarter. Quest Partners LLC now owns 41,492 shares of the medical equipment provider's stock worth $3,081,000 after acquiring an additional 14,914 shares during the period. Finally, Versor Investments LP purchased a new position in Hologic in the third quarter worth approximately $1,677,000. Hedge funds and other institutional investors own 94.73% of the company's stock.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on HOLX shares. JPMorgan Chase & Co. boosted their price objective on shares of Hologic from $92.00 to $94.00 and gave the stock an "overweight" rating in a research report on Tuesday, November 5th. StockNews.com upgraded shares of Hologic from a "hold" rating to a "buy" rating in a research note on Thursday, November 14th. Jefferies Financial Group started coverage on Hologic in a report on Tuesday, December 10th. They issued a "hold" rating and a $85.00 target price for the company. Needham & Company LLC reaffirmed a "buy" rating and issued a $90.00 target price on shares of Hologic in a report on Thursday, December 19th. Finally, Evercore ISI upped their target price on shares of Hologic from $78.00 to $82.00 and gave the company an "in-line" rating in a report on Tuesday, October 1st. Six equities research analysts have rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $89.50.

Insider Buying and Selling at Hologic

In other news, COO Essex D. Mitchell sold 24,856 shares of the firm's stock in a transaction that occurred on Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total transaction of $1,897,507.04. Following the completion of the sale, the chief operating officer now owns 27,957 shares of the company's stock, valued at approximately $2,134,237.38. This trade represents a 47.06 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 1.75% of the stock is currently owned by corporate insiders.

Hologic Trading Up 0.1 %

HOLX stock traded up $0.04 during trading on Thursday, reaching $72.72. 1,349,940 shares of the stock traded hands, compared to its average volume of 1,672,441. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.69 and a quick ratio of 3.03. Hologic, Inc. has a 52-week low of $70.36 and a 52-week high of $84.67. The firm has a market capitalization of $16.50 billion, a PE ratio of 21.84, a P/E/G ratio of 2.38 and a beta of 0.96. The business's 50 day moving average price is $77.79 and its 200-day moving average price is $78.45.

Hologic (NASDAQ:HOLX - Get Free Report) last released its quarterly earnings data on Monday, November 4th. The medical equipment provider reported $1.01 EPS for the quarter, meeting the consensus estimate of $1.01. Hologic had a return on equity of 19.79% and a net margin of 19.59%. The company had revenue of $987.90 million for the quarter, compared to analyst estimates of $978.25 million. During the same period last year, the company posted $0.89 earnings per share. The firm's revenue was up 4.5% compared to the same quarter last year. As a group, sell-side analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.